Protara reports Q4 net loss of $10.2M; cash $65.6M; TARA-002 data milestones in 2024

Protara Therapeutics, Inc.

Net loss Q4 2023: $10.2M ($0.90/share); full-year net loss $40.4M ($3.57/share).
Cash, equivalents & investments $65.6M as of Dec 31, 2023; runway into Q2 2025.
R&D expenses Q4 $6.4M (up from $5.0M YoY); full-year $25.0M (up from $16.8M).
Preliminary ADVANCED-1EXP TARA-002 data in NMIBC CIS expected 1H 2024; ADVANCED-2 data in 2H 2024.
Dosing underway in STARBORN-1 Phase 2 trial of TARA-002 for lymphatic malformations.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Protara Therapeutics, Inc. reported the full year and fourth quarter ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023 was $40.4 million, or $3.57 per share, EPS $3.57 per share.

Period: the full year and fourth quarter ended December 31, 2023
Net income: Net loss for the year ended December 31, 2023 was $40.4 million, or $3.57 per share
EPS: $3.57 per share
Result: reported results

Exact text from the filing

Protara Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2023

View on SEC.gov

Browse all earnings releases →

Protara Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-021981

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.